On August 7, 2023 Hubro Therapeutics reported that NOK 41,1 mill has been raised in a private placement (Press release, Hubro Therapeutics, AUG 7, 2023, View Source [SID1234635192]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funds will be used to continue the company’s development of lead candidate vaccine FMPV-1, adjuvant GM-CSF and companion diagnostics, as well as preparing for initiation of the phase 2 study with FMPV-1/GM-CSF in MSI-colorectal cancer.